Xion Pharmaceuticals Private Limited

Trading pharmaceutical products for improved healthcare.

2007 | Pune, Maharashtra (India) | Active
Last Updated:

Xion Pharmaceuticals Profile

Key Indicators

  • Authorised Capital ₹ 1.00 M
  • Paid Up Capital ₹ 0.10 M
  • Company Age 17 Year, 9 Months
  • Last Filing with ROC 31 Mar 2024
  • Open Charges ₹ 8.00 M
  • Revenue Growth -42.30%
  • Profit Growth -93.85%
  • Ebitda -73.72%
  • Net Worth 0.43%
  • Total Assets 0.06%

About Xion Pharmaceuticals

Xion Pharmaceuticals Private Limited (XPPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 June 2007 and has a history of 17 years and nine months. Its registered office is in Pune, Maharashtra, India.

The Corporate was formerly known as Jodhawat Enterprises Private Limited. The Company is engaged in the Pharma Industry.

The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.

The company currently has active open charges totaling ₹8.00 M.

Mahendra Jain, Rajeshkumar Jain, and Roshan Jain serve as directors at the Company.

Company Details

  • Location

    Pune, Maharashtra, India

  • Telephone

    +91-XXXXXXXXXX

  • Email Address

  • Website

    -

  • Social Media
    -

Corporate Identity Details

  • CIN/LLPIN

    U24231PN2007PTC130248

  • Company No.

    130248

  • Company Classification

    Private Limited Indian Non-Government Company

  • Incorporation Date

    04 Jun 2007

  • Date of AGM

    30 Sep 2024

  • Date of Balance Sheet

    31 Mar 2024

  • Listing Status

    Unlisted

  • ROC Code

    Roc Pune

Industry

Pharma

Who are the key members and board of directors at Xion Pharmaceuticals?

Board Members (3)

NameDesignationAppointment DateStatus
Mahendra Jain Country flag representing In Director 04-Jun-2007Current
Rajeshkumar Jain Country flag representing In Director 04-Jun-2007Current
Roshan Jain Country flag representing In Director 04-Jun-2007Current

Financial Performance of Xion Pharmaceuticals.

Xion Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 42.3% decrease. The company also saw a substantial fall in profitability, with a 93.85% decrease in profit. The company's net worth moved up by a moderate rise of 0.43%.

Xion Pharmaceuticals revenue growth over time
Xion Pharmaceuticals profit and loss trends over time
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023)YOY Growth
(FY 2022)(FY 2021)(FY 2020)(FY 2019)
Total Revenue
-42.30%
Revenue from Operations
-42.33%
Total Assets
0.06%
Profit or Loss
-93.85%
Net Worth
0.43%
EBITDA
-73.72%

What is the Ownership and Shareholding Structure of Xion Pharmaceuticals?

In 2020, Xion Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Indicator graph

Charges (Loans)

Open Charges

₹8.00 M

Satisfied Charges

₹0

Charges Breakdown by Lending Institutions

  • The Cosmos Co-Operative Bank Limited : 0.55 Cr
  • Others : 0.25 Cr

Latest Charge Details

DateLenderAmountStatus
07 Feb 2017Others₹2.50 MOpen
26 Mar 2014The Cosmos Co-Operative Bank Limited₹5.50 MOpen

How Many Employees Work at Xion Pharmaceuticals?

Unlock and access historical data on people associated with Xion Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee growth trends for Xion Pharmaceuticals Private Limited

Deals i

Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Xion Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xion Pharmaceuticals's trajectory.

Rating

Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts

Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Latest Updates, News, and FAQs on Xion Pharmaceuticals

Recent activity within the organization

  • Annual General Meeting

    Xion Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.

  • Balance Sheet

    Xion Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Pune.

  • Charges

    A charge with Others amounted to Rs. 2.50 M with Charge ID 100080448 was registered on 07 Feb 2017.

  • Charges

    A charge with The Cosmos Co-Operative Bank Limited amounted to Rs. 5.50 M with Charge ID 10495952 was registered on 26 Mar 2014.

  • Director Appointment

    Mahendra Champalal Jain was appointed as a Director was appointed as a Director on 04 Jun 2007 & has been associated with this company since 17 years 9 months .

  • Director Appointment

    Rajeshkumar Champalal Jain was appointed as a Director was appointed as a Director on 04 Jun 2007 & has been associated with this company since 17 years 9 months .

Frequently asked questions

  • What is the Incorporation or founding date of Xion Pharmaceuticals Private Limited?

    Xion Pharmaceuticals Private Limited was incorporated on 04 Jun 2007.

  • What is authorized share capital and paid-up capital of Xion Pharmaceuticals Private Limited?

    The authorized share capital of Xion Pharmaceuticals Private Limited is ₹ 1.00 M and paid-up capital is ₹ 0.10 M.

  • Who are the current board members & directors of Xion Pharmaceuticals Private Limited?

    Currently 3 directors are associated with Xion Pharmaceuticals Private Limited.

    • Mahendra Champalal Jain
    • Rajeshkumar Champalal Jain
    • Roshan Champalal Jain

  • What is the registered address of Xion Pharmaceuticals Private Limited?

    As per Ministry of Corporate Affairs (Mca), the registered address of Xion Pharmaceuticals Private Limited is Office No. 102 103 Park Plaza First Floor Opp Kamala Nehru Park Erandwane, India, Pune, Maharashtra, 411004.

  • What is the corporate identification number (CIN) and company number of Xion Pharmaceuticals Private Limited?

    The corporate identification number (CIN) of Xion Pharmaceuticals Private Limited is U24231PN2007PTC130248 and the company number is 130248 as per Ministry of Corporate Affairs (MCA).

  • What has been the recent revenue trend for Xion Pharmaceuticals Private Limited?

    According to the financial reports for the fiscal year 2023, the revenue trend for Xion Pharmaceuticals Private Limited has fallen by -42.30%.

  • What change has been observed in the net worth of Xion Pharmaceuticals Private Limited, and by what percentage?

    The financial reports for the fiscal year 2023 indicates that The net worth of Xion Pharmaceuticals Private Limited has experienced an upsurge of 0.43%.

  • What are the total open charges for Xion Pharmaceuticals Private Limited?

    As per the financial statements for fiscal Year 2023, The total open charges for Xion Pharmaceuticals Private Limited amount to ₹ 8.00 M.

  • When was the last Balance Sheet of Xion Pharmaceuticals Private Limited filed with the ROC?

    The most recent Balance Sheet for Xion Pharmaceuticals Private Limited was filed with the ROC on 31 Mar 2024.